clinical trial
AstraZeneca Advancing Plan to Launch Biomarker-Driven Drugs as Alternative to Chemo in Breast Cancer
Premium
The drugmaker wants to establish Enhertu in HER2-ultralow breast cancer and even HER2-negative tumors but remains committed to precision medicine strategies.
Pierre Fabre, Scorpion Therapeutics Begin Phase I/II Trial in 'Double-Mutant' NSCLC Patients
The partners are studying a drug designed to target EGFR exon 19 or exon 21 mutations with a co-occurring C797S mutation.
TheraVectys Launches Phase I/IIa Trial of HPV-Targeted Vaccine in Cervical, Oropharyngeal Cancers
The trial will include patients with newly diagnosed, treatment-naïve cancers as well as those with recurrent or metastatic disease.
AstraZeneca, Daiichi Sankyo's Enhertu BLA in HER2-Low, Ultralow Breast Cancer Gets FDA Priority Review
The FDA expects to issue a decision in the first quarter of 2025, and if the agency grants approval, it will expand the biomarker-eligible population for the drug.
BioAI, Arbele Team up to Develop AI-Based Biomarker Screening Test
The companies will initially develop an AI-based test to select patients with CDH17-expressing gastrointestinal cancers for Arbele's Phase I drug trial.
Aug 27, 2024